HOME >> BIOLOGY >> NEWS
Experimental therapy stops allergic reactions in mice

Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) have devised a new, experimental approach to treating allergic diseases. In mice, the scientists used a genetically engineered molecule to connect two receptors on the key immune system cells that cause allergic reactions. Cross-linking these receptor molecules short-circuited the type of allergic reaction that leads to asthma, allergic rhinitis, and even the potentially deadly anaphylaxis caused by food allergy.

This work represents an entirely new approach to treating allergic diseases, says NIAID Director Anthony S. Fauci, M.D. The prevalence of allergic disease has increased significantly in recent decades, and there simply are not many promising therapeutic strategies out there. We hope that NIAIDs continued support of research into the mechanisms of allergy will lead to other innovative concepts like this one.

This research does what science is supposed to do, says Marshall Plaut, M.D., chief of NIAIDs Allergic Mechanisms Section. The researchers succeeded in translating a scientific observation into a clever therapeutic idea. Details of this work, performed by a team of scientists at the University of California at Los Angeles (UCLA) and the University of New Mexico, appear in the May issue of Nature Medicine.

The scientists designed and created a molecule called GE2 that acts on two types of immune system cells central to allergic reactions: mast cells and basophils. In people with allergies, these cells respond to ordinarily harmless substances, such as pollen or peanut proteins, by releasing chemicals such as histamine that trigger the symptoms of allergic reactions. Histamine, for example, causes swelling, sneezing, itching, and irritation.

GE2 binds to receptor molecules on mast cells and basophils that control the release of histamine. One of these receptor molecules is like a gas pedal: it makes the allergic reaction go.
'"/>

Contact: Jeff Minerd
jminerd@niaid.nih.org
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
30-Apr-2002


Page: 1 2

Related biology news :

1. Experimental drug shown to block mutant protein causing blood disease
2. Experimental smallpox DNA vaccine protects primates from lethal monkeypox
3. Experimental smallpox vaccine protects against monkeypox in nonhuman primates
4. Experimental Biology 2004 - Translating the Genome
5. Experimental Biology 2004 meets in Washington, D.C. April 17-21
6. Experimental hantavirus vaccine elicits strong antibody response in primates
7. Experimental cancer drugs may halt events that lead to cardiac hypertrophy and heart failure
8. Experimental Biology 2003 meets in San Diego April 11-15
9. Experimental Biology 2003 meets in San Diego April 11-15
10. Experimental gene switch increases lifespan with no ill effects
11. APS awards 44 minority travel fellowships to the Experimental Biology 2002 meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/13/2019)... MOUNTAIN VIEW, Calif. (PRWEB) , ... March 13, 2019 , ... ... for up to 45 percent of the world’s population. One billion ... person's breathing is interrupted during sleep - more than 80 percent of whom go ...
(Date:3/12/2019)... (PRWEB) , ... March 12, 2019 , ... ... strong multi-factor authentication and combined technology all-in-one smart cards, announced today the launch ... strong authentication: the Fingerprint Biometric and Dynamic CVV Payment cards. These advanced technologies ...
(Date:3/9/2019)... (PRWEB) , ... March 07, 2019 , ... ... and infectious disease diagnostics and automation – is pleased to announce the launch ... control resource giving customers access to lot-specific information, including pattern images for AESQC ...
Breaking Biology News(10 mins):
(Date:3/9/2019)... ... March 08, 2019 , ... ... planning, announced the release of their Best Online Master's in Biotechnology Programs ... on curriculum quality, program flexibility, affordability, and graduate outcomes. , In addition ...
(Date:3/4/2019)... ... March 04, 2019 , ... Stay on top of current hot topics through free webinars ... webinars is free, so be sure to register today to save your place! Participate in ... our upcoming webinars: , CLINICAL TRIALS, , March 20 – Implementing ...
(Date:2/26/2019)... (PRWEB) , ... February 26, 2019 , ... ... 2012 when Visikol Co-Founder Dr. Thomas Villani developed the Visikol® tissue clearing technology ... and has since transitioned from a products focused company to primarily a services ...
(Date:2/22/2019)... ... 2019 , ... Ocean Tomo Transactions, LLC will auction a ... patents in lot 92 relate to innovation for verifying human users ... users and computers through exploiting the fundamental differences between computer-based vision and human ...
Breaking Biology Technology:
Cached News: